The Chronic Urticaria or Hives Drug Market was valued at USD 3.4 Billion in 2022 and is projected to reach USD 7.2 Billion by 2030, growing at a CAGR of 9.7% from 2024 to 2030. The market is witnessing significant growth due to the increasing prevalence of chronic urticaria, rising awareness about available treatments, and advancements in drug development. In addition, the market is driven by the growing demand for biologic therapies, which are being increasingly recognized for their effectiveness in managing severe cases of chronic hives.
As the treatment landscape evolves, novel therapeutic options such as monoclonal antibodies are expected to fuel market growth. The rise in healthcare spending and improvements in healthcare infrastructure in emerging regions also contribute to the growing demand for chronic urticaria drugs. Additionally, the market's expansion is supported by the rising adoption of personalized medicine, allowing for more targeted treatments. The shift towards biologics and novel oral therapies is anticipated to significantly shape the market trajectory in the coming years.
Download Full PDF Sample Copy of Market Report @
Chronic Urticaria Or Hives Drug Market Research Sample Report
Chronic urticaria, commonly known as chronic hives, is a skin condition characterized by the frequent appearance of raised, red, itchy welts on the skin, often without a known cause. The chronic form of urticaria lasts for six weeks or longer and can significantly affect an individual's quality of life. In treating chronic urticaria, the market for drugs is segmented by different applications, including clinical, hospital, and others. These application segments represent diverse areas of care where drugs are utilized to manage symptoms and provide relief for patients suffering from this condition. The demand for medications for chronic urticaria has grown steadily as awareness about the condition increases and more advanced treatment options become available. The application by clinical settings, hospitals, and other care settings helps drive the market growth as patients seek treatment options that can provide long-term relief.
The "clinic" application segment includes both private and outpatient clinics where patients seek medical attention for chronic urticaria. In clinical settings, dermatologists or allergy specialists typically diagnose and treat patients using a variety of available drug therapies. The most commonly used treatments in clinics include antihistamines, corticosteroids, and immunosuppressive agents, which help control symptoms like itching, swelling, and redness. In recent years, biologic drugs have emerged as a cutting-edge option in clinical practice for more severe cases of chronic urticaria. This market segment is witnessing strong growth due to the increasing number of specialty clinics focused on managing chronic conditions like urticaria and the broader adoption of advanced therapies. As patients look for personalized treatment options, clinics remain one of the primary care points for treating chronic urticaria, further supporting market expansion.
The "hospital" application segment encompasses care settings in hospitals, including emergency departments, dermatology wards, and allergy and immunology departments, where patients with chronic urticaria may receive acute care and ongoing treatment. Hospitals play a significant role in treating severe cases of chronic urticaria that do not respond to standard treatments or those that require immediate intervention. Hospital-based treatment options may include intravenous biologics, corticosteroids, and other therapies under close medical supervision. Additionally, patients who suffer from comorbid conditions related to chronic urticaria may be managed in hospital settings, ensuring comprehensive care. The growing demand for specialized hospital services for chronic urticaria and the increasing use of biologic therapies contribute to the expanding market for drugs in this segment. The rise of patient awareness about available hospital treatments for chronic urticaria also boosts this market subsegment's potential.
The "others" segment in the chronic urticaria drug market includes various alternative care settings, such as home care, online consultations, telemedicine platforms, and over-the-counter (OTC) drug sales. As patients seek convenience, many are turning to online consultations with healthcare professionals who prescribe drugs that can be used at home, such as antihistamines or topical creams for symptomatic relief. Over-the-counter medications also play an important role in managing mild symptoms of chronic urticaria, providing patients with accessible solutions without the need for a prescription. Additionally, home care options, where patients manage their symptoms through prescribed medications and lifestyle changes, are gaining popularity. The "others" segment also includes health and wellness clinics that offer treatments like acupuncture or herbal medicine as adjuncts to traditional pharmacological therapies. The growing inclination towards telemedicine and home-based care options, especially in the post-pandemic world, is expected to drive the growth of the "others" segment in the chronic urticaria drug market.
One of the major trends in the chronic urticaria drug market is the increasing shift toward biologic therapies. These biologic treatments, such as omalizumab (Xolair), have shown promising results in patients who do not respond to traditional antihistamines and corticosteroids. Biologics are expected to capture a significant market share due to their efficacy in managing moderate to severe cases of chronic urticaria. With advancements in biotechnology, new biologics are emerging, offering more treatment options for patients, which creates a large market opportunity for pharmaceutical companies to invest in research and development for these specialized therapies. Additionally, the expanding knowledge of the immunologic mechanisms behind chronic urticaria has led to targeted therapies that are likely to provide more tailored treatment approaches, improving patient outcomes.
Another significant trend is the growing adoption of telemedicine and digital health tools in managing chronic urticaria. As patients increasingly seek convenience, online consultations and telehealth platforms are becoming more integrated into the management of this condition. This trend is expected to provide opportunities for healthcare providers to expand their services to a wider population. Furthermore, advancements in diagnostic tools, such as skin tests and blood tests, enable clinicians to more accurately identify chronic urticaria subtypes and tailor treatments accordingly. Opportunities also lie in increasing patient awareness and education about chronic urticaria, which can drive demand for treatments and help reduce the burden of the disease on healthcare systems.
What is chronic urticaria?
Chronic urticaria is a condition characterized by itchy, raised welts or hives on the skin lasting for six weeks or longer, with no known cause in many cases.
What are the main treatments for chronic urticaria?
Common treatments for chronic urticaria include antihistamines, corticosteroids, and biologic therapies like omalizumab for severe cases.
Can chronic urticaria be cured?
While chronic urticaria may not have a definitive cure, its symptoms can often be managed effectively with medications and lifestyle changes.
Are biologic drugs effective for chronic urticaria?
Yes, biologic drugs, particularly omalizumab, have shown significant efficacy in treating moderate to severe chronic urticaria that does not respond to conventional therapies.
What is the role of antihistamines in chronic urticaria treatment?
Antihistamines are the first-line treatment for chronic urticaria, helping to reduce itching and swelling caused by histamine release in the skin.
Can over-the-counter medications help with chronic urticaria?
Over-the-counter antihistamines and creams can provide temporary relief from mild symptoms of chronic urticaria, though they are not a long-term solution.
How can lifestyle changes affect chronic urticaria management?
Lifestyle changes such as avoiding triggers, stress management, and maintaining a healthy diet can help alleviate symptoms of chronic urticaria.
Is chronic urticaria linked to any other health conditions?
Chronic urticaria may sometimes be associated with autoimmune diseases, infe
For More Information or Query, Visit @ Chronic Urticaria Or Hives Drug Market Size And Forecast 2025-2030
Â